Processing

Please wait...

Settings

Settings

Goto Application

1. WO2011003062 - PROBIOTIC COMPOSITIONS AND PROCESSES THEREOF

Publication Number WO/2011/003062
Publication Date 06.01.2011
International Application No. PCT/US2010/040898
International Filing Date 02.07.2010
IPC
A61K 36/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
36Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
06Fungi, e.g. yeasts
A61K 39/02 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
A61K 39/12 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
C07K 7/54 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
50Cyclic peptides containing at least one abnormal peptide link
54with at least one abnormal peptide link in the ring
A61P 17/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
17Drugs for dermatological disorders
A61P 3/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
CPC
A61K 35/74
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
74Bacteria
A61P 17/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
17Drugs for dermatological disorders
A61P 3/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
A61P 31/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
04Antibacterial agents
A61P 31/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
10Antimycotics
A61P 31/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
Applicants
  • JAMES MADISON INNOVATIONS, INC. [US]/[US] (AllExceptUS)
  • MINBIOLE, Kevin, P.C. [US]/[US] (UsOnly)
  • HARRIS, Reid [US]/[US] (UsOnly)
Inventors
  • MINBIOLE, Kevin, P.C.
  • HARRIS, Reid
Agents
  • RODRIGUEZ, Edgar, G.
Priority Data
12/829,52002.07.2010US
61/222,96403.07.2009US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) PROBIOTIC COMPOSITIONS AND PROCESSES THEREOF
(FR) COMPOSITIONS PROBIOTIQUES ET PROCÉDÉS S'Y RAPPORTANT
Abstract
(EN)
Probiotic composition(s) and/or process(es) thereof. Processes may include applying Janthinobacterium, for example Janthinobacterium Lividum, over a host and/or host area(s) to minimize microbe(s) and/or maximize therapeutic effects. A process to minimize a microbe may include applying to skin a composition including isolated Janthinobacterium Lividum and a pharmaceutically acceptable carrier. Probiotic composition(s) and/or process(es) thereof may include relatively heat tolerant Janthinobacterium Lividum which may produce metabolites, for example violacein up to approximately 29 °C, Probiotic composition(s) and/or process(es) thereof may include Janthinobacterium Lividum between approximately 25x106 and 6.4x107 cells. Probiotic composition(s) and/or process(es) thereof may include Janthinobacterium Lividum which has and/or produces between approximately 18 μM and 129 μM of violacein. Probiotic composition(s) and/or process(es) thereof may include a stimulant to maximize metabolites. A process to minimize a microbe may include removing a portion of resident microbes with a sanitizer. Janthinobacterium Lividum may be in lysed form.
(FR)
Cette invention concerne une ou des compositions probiotiques et/ou un ou des procédés s'y rapportant. Les procédés peuvent comprendre l'application d'un Janthinobacterium, par exemple, Janthinobacterium Lividum, à un hôte et/ou à une ou des zones hôtes pour minimiser le(s) microbe(s) et/ou maximiser les effets thérapeutiques. Un procédé destiné à minimiser un microbe peut comprendre l'application à la peau d'une composition comprenant un Janthinobacterium Lividum isolé et un véhicule pharmaceutiquement acceptable. La ou les compositions probiotiques et/ou procédé(s) s'y rapportant peuvent comprendre un Janthinobacterium Lividum relativement tolérant à la chaleur qui peut produire des métabolites, par exemple, de la violacéine jusqu'à environ 29°C. La ou les compositions probiotiques et/ou procédé(s) s'y rapportant peuvent comprendre un Janthinobacterium Lividum en une quantité comprise entre environ 25x106 et 6,4x107 cellules. La ou les compositions probiotiques et/ou procédé(s) s'y rapportant peuvent comprendre un Janthinobacterium Lividum qui a et/ou produit entre environ 18 et 129 μM de violacéine. La ou les compositions probiotiques et/ou procédé(s) s'y rapportant peuvent comprendre un stimulant pour maximiser les métabolites. Un procédé destiné à minimiser un microbe peut comprendre l'élimination d'une partie des microbes résidents avec un assainisseur. Janthinobacterium Lividum peut être sous une forme lysée.
Latest bibliographic data on file with the International Bureau